Cargando…

Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer

BACKGROUND: Cervical cancer is the fourth most frequent gynecological malignancy across the world. Immunotherapies have proved to improve prognosis of cervical cancer. However, few studies on immune-related prognostic signature had been reported in cervical cancer. METHODS: Raw data and clinical inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Rongjia, Jin, Chengwen, Bu, Hualei, Xiang, Jiangdong, Zhou, Lina, Jin, Chengjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148954/
https://www.ncbi.nlm.nih.gov/pubmed/35651784
http://dx.doi.org/10.3389/fonc.2022.861392
_version_ 1784717115368931328
author Su, Rongjia
Jin, Chengwen
Bu, Hualei
Xiang, Jiangdong
Zhou, Lina
Jin, Chengjuan
author_facet Su, Rongjia
Jin, Chengwen
Bu, Hualei
Xiang, Jiangdong
Zhou, Lina
Jin, Chengjuan
author_sort Su, Rongjia
collection PubMed
description BACKGROUND: Cervical cancer is the fourth most frequent gynecological malignancy across the world. Immunotherapies have proved to improve prognosis of cervical cancer. However, few studies on immune-related prognostic signature had been reported in cervical cancer. METHODS: Raw data and clinical information of cervical cancer samples were downloaded from TCGA and UCSC Xena website. Immunophenoscore of immune infiltration cells in cervical cancer samples was calculated through the ssGSEA method using GSVA package. WGCNA, Cox regression analysis, LASSO analysis, and GSEA analysis were performed to classify cervical cancer prognosis and explore the biological signaling pathway. RESULTS: There were eight immune infiltration cells associated with prognosis of cervical cancer. Through WGCNA, 153 genes from 402 immune-related genes were significantly correlated with prognosis of cervical cancer. A 15-gene signature demonstrated powerful predictive ability in prognosis of cervical cancer. GSEA analysis showed multiple signaling pathways containing Programmed cell death ligand-1 (PD-L1) expression and PD-1 checkpoint pathway differences between high-risk and low-risk groups. Furthermore, the 15-gene signature was associated with multiple immune cells and immune infiltration in tumor microenvironment. CONCLUSION: The 15-gene signature is an effective potential prognostic classifier in the immunotherapies and surveillance of cervical cancer.
format Online
Article
Text
id pubmed-9148954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91489542022-05-31 Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer Su, Rongjia Jin, Chengwen Bu, Hualei Xiang, Jiangdong Zhou, Lina Jin, Chengjuan Front Oncol Oncology BACKGROUND: Cervical cancer is the fourth most frequent gynecological malignancy across the world. Immunotherapies have proved to improve prognosis of cervical cancer. However, few studies on immune-related prognostic signature had been reported in cervical cancer. METHODS: Raw data and clinical information of cervical cancer samples were downloaded from TCGA and UCSC Xena website. Immunophenoscore of immune infiltration cells in cervical cancer samples was calculated through the ssGSEA method using GSVA package. WGCNA, Cox regression analysis, LASSO analysis, and GSEA analysis were performed to classify cervical cancer prognosis and explore the biological signaling pathway. RESULTS: There were eight immune infiltration cells associated with prognosis of cervical cancer. Through WGCNA, 153 genes from 402 immune-related genes were significantly correlated with prognosis of cervical cancer. A 15-gene signature demonstrated powerful predictive ability in prognosis of cervical cancer. GSEA analysis showed multiple signaling pathways containing Programmed cell death ligand-1 (PD-L1) expression and PD-1 checkpoint pathway differences between high-risk and low-risk groups. Furthermore, the 15-gene signature was associated with multiple immune cells and immune infiltration in tumor microenvironment. CONCLUSION: The 15-gene signature is an effective potential prognostic classifier in the immunotherapies and surveillance of cervical cancer. Frontiers Media S.A. 2022-05-16 /pmc/articles/PMC9148954/ /pubmed/35651784 http://dx.doi.org/10.3389/fonc.2022.861392 Text en Copyright © 2022 Su, Jin, Bu, Xiang, Zhou and Jin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Su, Rongjia
Jin, Chengwen
Bu, Hualei
Xiang, Jiangdong
Zhou, Lina
Jin, Chengjuan
Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
title Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
title_full Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
title_fullStr Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
title_full_unstemmed Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
title_short Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer
title_sort development and validation of an immune-related prognostic signature in cervical cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148954/
https://www.ncbi.nlm.nih.gov/pubmed/35651784
http://dx.doi.org/10.3389/fonc.2022.861392
work_keys_str_mv AT surongjia developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer
AT jinchengwen developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer
AT buhualei developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer
AT xiangjiangdong developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer
AT zhoulina developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer
AT jinchengjuan developmentandvalidationofanimmunerelatedprognosticsignatureincervicalcancer